The Washington State University Office of Commercialization is proud to announce that M3 Biotechnology, one of our local startup companies, has been selected as one of five companies to be showcased by the Michael J. Fox Foundation for their work on neurodegenerative disease therapies. The MJFF aims to accelerate the research and development of projects in Parkinson’s disease research by making the researchers and projects more visible.
M3 Biotechnology’s mission statement, ‘To cure neurodegenerative diseases’ is a straightforward explanation of their goals and projects. The group was already supported from grants from the MJFF as well as the Alzheimer’s Drug Discovery foundation, groups highly interested in finding treatments for and reversing the effects of neurodegenerative diseases. Alzheimer’s and Parkinson’s, while manifesting in significantly different ways, both originate in the degradation of the central nervous system. People with Alzheimer’s find their synaptic responses and memory fade while people with Parkinson’s slowly lose fine muscle control. Thanks to M3’s therapeutic treatments, they have found drugs and therapies that can reduce or even reverse the clinical courses of these diseases.
M3 Biotechnologies has been chosen by the MJFF to push the MM-201 development, their oral drug designed to reverse the neurodegenerative effects of Parkinson’s disease. For more information, read more at the Michael J Fox Foundation website here.